For the quarter ending 2025-09-30, ASMB had -$1,472K decrease in cash & cash equivalents over the period. -$15,175K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Collaboration revenue from a related party | 29,834 | - |
| ABIFive Three Six Six | 7,158 | - |
| ABIOne One Seven Nine | 5,047 | - |
| ABISix Two Five Zero | 4,617 | - |
| ABIFour Three Three Four | 919 | - |
| ABISeven Two Seven Two | 2,004 | - |
| Research And Discovery | 5,839 | - |
| Vebicorvir | 0 | - |
| Total external program expenses | 25,584 | - |
| Employee and contractor-related expenses | 19,365 | - |
| Facility and other expenses | 2,614 | - |
| Total research and development | 47,563 | - |
| General and administrative | 14,188 | - |
| Interest and other income, net | 3,705 | - |
| Income tax expense | 0 | - |
| Net loss | -9,196 | -19,016 |
| Depreciation and amortization | 32 | 65 |
| Stock-based compensation | 1,670 | 1,546 |
| Net accretion of investments in marketable debt securities | 631 | 887 |
| Non-cash rent expense | 209 | 438 |
| Accounts receivable from collaboration (-912 and - from a related party) | 912 | 0 |
| Prepaid expenses and other current assets | 856 | -937 |
| Accounts payable | 940 | 158 |
| Accrued research and development expenses | 1,367 | -582 |
| Other accrued expenses | 2,321 | -3,455 |
| Deferred revenue from a related party | -9,877 | -19,045 |
| Operating lease liabilities | -200 | -356 |
| Net cash used in operating activities | -15,133 | -40,197 |
| Proceeds from maturities of marketable securities | 22,700 | 60,932 |
| Purchases of marketable securities | 180,929 | 37,352 |
| Purchases of property and equipment | 42 | 0 |
| Net cash (used in) provided by investing activities | -158,271 | 23,580 |
| Proceeds from the issuance of common stock, pre-funded warrants and warrants in an underwritten offering, net of issuance costs | 123,600 | - |
| Proceeds from the issuance of common stock and warrants in private placements to a related party, net of issuance costs | 42,785 | 0 |
| Proceeds from the exercise of warrants | 5,510 | - |
| Proceeds from the issuance of common stock under atm equity offering program, net of issuance costs | 0 | 1,922 |
| Proceeds from the issuance of common stock under espp | 0 | 357 |
| Proceeds from the exercise of stock options | 37 | 0 |
| Proceeds from the issuance of common stock and warrants in a registered direct offering and a private placement, net of issuance costs | 0 | 0 |
| Net cash provided by financing activities | 171,932 | 2,279 |
| Net (decrease) increase in cash and cash equivalents | -1,472 | -14,338 |
| Cash and cash equivalents at beginning of period | 38,344 | - |
| Cash and cash equivalents at end of period | 22,534 | - |
ASSEMBLY BIOSCIENCES, INC. (ASMB)
ASSEMBLY BIOSCIENCES, INC. (ASMB)